The 20th Anniversary of Medicilon's Establishment-Outlook of KOLs

Medicilon has had many challenges in its 20 years. Especially, we are witnessing a turning point in China's pharmaceutical R&D, including CRO. I hope that Medicilon will become a fertile ground for incubating and promoting genuine innovative drugs in China in the future. Not just rely on commissioned work but also increasingly participate in collaborative R&D and move from me-too towards upstream innovation. 

Medicilon should build a solid technical platform, actively following the development of new technologies and methods, and providing clients with more professional and precise services, further expanding into the international market and become a leading CRO company globally. Representing Chinese enterprises to speak up internationally and helping Chinese pharmaceutical companies rise and soar worldwide. Medicilon stands at the forefront of industry development according to the needs of the times, striving to promote the development of the pharmaceutical industry and creating a brighter future.

Medicilon is grateful for the love and support from all of you in pharmaceutical industry.